Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder.
Expert Opin Pharmacother. 2023 Apr;24(5):641-654. doi: 10.1080/14656566.2023.2194488. Epub 2023 Mar 24.
Expert Opin Pharmacother. 2023.
PMID: 36946229
Review.
We searched PubMed, MedLine, and PsycInfo from inception to December 1(st,) 2022. Traditional treatments, such as lithium, anticonvulsants (lamotrigine), antipsychotics (aripiprazole, asenapine, cariprazine, lurasidone, and olanzapine), antidepressants (vortioxetine, fluox …
We searched PubMed, MedLine, and PsycInfo from inception to December 1(st,) 2022. Traditional treatments, such as lithium, anticonvul …
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, Popescu BO, Tanasescu R.
Dumitrescu L, et al.
Expert Opin Pharmacother. 2023 Mar;24(4):495-509. doi: 10.1080/14656566.2023.2178898. Epub 2023 Mar 22.
Expert Opin Pharmacother. 2023.
PMID: 36946625
Free PMC article.
Review.
They restrain the S1P-dependent lymphocyte egress from lymph nodes by binding the lymphocytic S1P-subtype-1-receptor. Depending on their pharmacodynamics and pharmacokinetics, they can also interfere with other biological functions. ...We briefly address their impact on th …
They restrain the S1P-dependent lymphocyte egress from lymph nodes by binding the lymphocytic S1P-subtype-1-receptor. Depending on th …
Item in Clipboard
Cite
Cite